• In recent months, Ripple Effect Asset Management acquired 510,000 shares of Antero Midstream Corporation and used put and call options alongside this position, while the company reported third-quarter results showing higher adjusted EBITDA, doubled free cash flow after dividends, lower leverage, and ongoing share repurchases.
• This combination of a new options-backed institutional stake and improving cash generation with balance sheet progress may influence how investors view Antero Midstream’s risk and income profile.
• Now we’ll explore how Ripple Effect’s options-backed stake and Antero Midstream’s stronger recent free cash flow shape the company’s investment narrative.

We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Antero Midstream Investment Narrative Recap

To own Antero Midstream, you need to believe its fee-based gathering and processing assets in Appalachia will keep generating dependable cash flows despite customer and regional concentration. Ripple Effect Asset Management’s options-backed stake, combined with stronger recent free cash flow and lower leverage, modestly supports the near term income and balance sheet story, but does not materially change the key catalyst of sustained volumes from Antero Resources or the biggest risk around that concentration.

Among recent announcements, the recurring US$0.225 quarterly dividend stands out as most relevant here, because it directly ties into the discussion of free cash flow and balance sheet capacity. With dividends held steady and share repurchases ongoing, the recent earnings strength provides some support for the current payout, but it also sharpens the question of how comfortably Antero Midstream can fund both income distributions and future growth projects if conditions tighten.

Yet behind the steady dividend and new institutional interest, there is a concentration risk in Appalachia and to Antero Resources that investors should be aware of...

Antero Midstream's narrative projects $1.3 billion revenue and $655.5 million earnings by 2028. This requires 1.3% yearly revenue growth and a $199.9 million earnings increase from $455.6 million today.

Uncover how Antero Midstream's forecasts yield a $18.64 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community range from US$14.20 to US$31,000.86, showing just how differently individual investors can view Antero Midstream. Set against this, the company’s heavy reliance on Antero Resources and Appalachian activity reminds you to weigh those diverse opinions against concrete customer and regional concentration risks before forming your own view.

Explore 4 other fair value estimates on Antero Midstream - why the stock might be worth 21% less than the current price!

Build Your Own Antero Midstream Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Antero Midstream research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Antero Midstream research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Antero Midstream's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 38 companies in the world exploring or producing it. Find the list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.